Compare PRLD & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRLD | SDHY |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.1M | 404.4M |
| IPO Year | 2020 | N/A |
| Metric | PRLD | SDHY |
|---|---|---|
| Price | $5.58 | $16.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | ★ 368.5K | 44.7K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | $15.17 |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.83 | $15.55 |
| 52 Week High | $5.91 | $17.18 |
| Indicator | PRLD | SDHY |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 45.97 |
| Support Level | $3.92 | $15.86 |
| Resistance Level | $5.62 | $16.23 |
| Average True Range (ATR) | 0.46 | 0.19 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 71.51 | 29.82 |
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.